is semaglutide different than tirzepatide Comparative safety and side effects of and tirzepatide: Implications for clinical decision-making in obesity management Tirzepatide vs Semaglutide: Which Weight

3g [25])

GLP-1 drug penetration below 4% of eligible patients Top GLP-1 market: United States with 62.8% of global GLP-1 weight loss drug revenue Cardiovascular approval catalyst: Wegovy approved for MACE risk reduction following SELECT trial demonstrating 20% reduction in major adverse cardiovascular events Fastest-growing indication: Obstructive sleep apnea at 41.2% CAGR following Zepbound FDA approval November 2025 Market Overview: Why GLP-1 Weight Loss Drug Market Growth Is Accelerating The GLP-1 Weight Loss Drug Market is at an unprecedented commercial inflection point defined by three simultaneous demand accelerators

doi:10.1016/j.celrep.2024.114501 28

Fast, reliable shipping on all orderstrack your package every step of the way

Values outside acceptable range were excluded (A1C: 0-20%, BMI: 0-100)